Surgeon experience is an independent predictor of PSA progression inmen undergoing radical prostatectomy, but among high-volume surgeons operatingin a single institution, the individual surgeon alone is a significant prognosticfactor, according to a study reported yesterday by researchers from MemorialSloan-Kettering Cancer Center, New York.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.